Additional Immunotherapies on the Horizon for LS-SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Atezolizumab is being tested in the NRG-LU005 trial for limited-stage SCLC, assessing its efficacy alongside chemoradiation.
The NRG-LU005 trial is a randomized, phase III study comparing chemoradiation with or without atezolizumab.
The ADRIATIC trial differs by focusing on extensive-stage SCLC, highlighting distinct trial objectives.
Using a single immunotherapy across all SCLC stages may streamline treatment protocols, offering potential synergies and efficiencies.

Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

Now Viewing

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

Atezolizumab is also being investigated in the NRG-LU005 trial in patients with limited-stage small cell lung cancer (SCLC).

What potential role could atezolizumab have in patients with limited-stage disease?
What is the design of this trial?
How does the trial design differ from the ADRIATIC trial?

Are there synergies or efficiencies in using a single immunotherapy in all stages of SCLC?

If a patient progresses from limited-stage to extensive-stage disease on immunotherapy, do you switch therapies or continue the same regimen?